EyePoint

Bull case

• EyePoint is supported by a compelling clinical and strategic setup, as DURAVYU showed positive secondary endpoints with a 42% reduction in treatment burden, 76% of patients supplement-free up to Week 32, and a 4-micron CST advantage at Week 56 versus aflibercept control.
• Even after LUGANO missed its Phase 3 non-inferiority primary endpoint, management cited strong anatomic outcomes, meaningful durability, and a favorable safety profile, while LUCIA remains on track to report topline data in 4Q26 and could support a pooled NDA submission in 1H27.
• The company’s broader pipeline, including EYP-2301 for vascular stability in retinal disease, and its focus on disease-modifying, lower-burden eye therapies create durable upside potential, reinforced by an upside scenario estimate of $8.

Bear case

EyePoint is facing a materially weaker fundamental outlook after LUGANO missed its prespecified primary non-inferiority endpoint in ITT, undermining confidence in DURAVYU and removing the simple two-positive-Phase-3 thesis investors had been underwriting. The negative read-through is compounded by unresolved questions about the asymmetric vision-loss cohort, which raises both efficacy and regulatory risk ahead of LUCIA data expected 4Q26 and leaves open whether the FDA would even approve on LUCIA alone. With the company still exposed to clinical execution risk, potential safety signals, competition, IP uncertainty, and financing risk that could require dilution before profitability, the downside case increasingly depends on cash and Yutiq revenue rather than pipeline value.